Pharmasset, Inc. Company Profile
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.
303-A College Road East
United States of America
Phone: (609) 613-4100
Fax: (609) 613-4150
ByAustrolib:Merck's (MRK) acquisition of Idenix (IDIX) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have been published on Seeki...
I think it is important to also point out that it cost Gilead $11 billion to acquire Pharmasset and thereby secure the rights to Sovaldi. They still had to pay costs associated with completing develo...
Two members of the Senate Finance Committee requested pricing information for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), including an explanation of the difference between th...
Gilead's hepatitis C drug, Solvaldi, sales have really taken off. Analysts are predicting megablockbuster status -- with high predictions of as much as $8 B in annual sales by as early as this year. T...
Sens. Ron Wyden, D-Ore., and Charles Grassley, R-Iowa, send letter to the drug's maker requesting information about how it set the price, which runs about $84,000 for a standard three-month regimen. T...
ByDoctoRx:Background: I have written twice about Gilead Sciences (GILD). A few weeks ago I wrote A Physician-Businessman's Views Of Gilead, With Emphasis On Sovaldi, and after the stock price and othe...
By Wall Street Playbook:The healthcare industry is highly competitive. Nowhere else does the term "survival of the fittest" proves true. In this sector, companies survive by maintaining strong drug pi...
ByGaurav S. Sharma:Gilead Sciences (GILD) has been a tremendous performer over the last few years as part of the multi-year biotech bull market. However, it has taken a significant dip in the past few...
Drugs and Medications
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...
More Information about "Pharmasset, Inc." on BioPortfolio
We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.